Based on the known biological functions of interleukin-15, one would predict that CAR T cells manufactured with interleukin-15 will exhibit **increased** release of effector cytokines (such as IFN-γ and TNF-α) upon antigen stimulation compared to CAR T cells manufactured without interleukin-15.